FORUM REVIEW ARTICLE

Redox Regulation of Heme Oxygenase-2 and the Transcription Factor, Rev-Erb, Through Heme Regulatory Motifs

Angela S. Fleischhacker, Eric L. Carter, and Stephen W. Ragsdale

Abstract

Significance: Heme binds to and serves as a cofactor for a myriad of proteins that are involved in diverse biological processes. Hemoproteins also exhibit varying modes of heme binding, suggesting that the protein environment contributes to the functional versatility of this prosthetic group. The subject of this review is a subset of hemoproteins that contain at least one heme regulatory motif (HRM), which is a short sequence containing a Cys-Pro core that, in many cases, binds heme with the Cys acting as an axial ligand.

Recent Advances: As more details about HRM-containing proteins are uncovered, some underlying commonalities are emerging, including a role in regulating protein stability. Further, the cysteines of some HRMs have been shown to form disulfide bonds. Because the cysteines must be in the reduced, dithiol form to act as a heme axial ligand, heme binds at these sites in a redox-regulated manner, as demonstrated for heme oxygenase-2 (HO2) and Rev-erb β .

Critical Issues: HRM-containing proteins have wide variations in heme affinity, utilize different axial ligand schemes, and exhibit differences in the ability to act as a redox sensor—all while having a wide variety of biological functions. Here, we highlight HO2 and Rev-erb β to illustrate the similarities and differences between two hemoproteins that contain HRMs acting as redox sensors.

Future Directions: HRMs acting as redox sensors may be applicable to other HRM-containing proteins as many contain multiple HRMs and/or other cysteine residues, which may become more evident as the functional significance of HRMs is probed in additional proteins. *Antioxid. Redox Signal.* 29, 1841–1857.

Keywords: heme, heme regulatory motif, disulfide, redox regulation, heme oxygenase, nuclear receptor

Introduction

THE HEME REGULATORY MOTIF (HRM) is a short sequence containing a Cys-Pro core that, in many cases, binds heme with the Cys acting as an axial ligand. HRMs are found in a diverse set of proteins that have a wide variety of biological functions, but the study of HRMs began in earnest only relatively recently. In 1989, the DNA sequence of heme activator protein 1 (Hap-1), a yeast transcription activator, revealed a short sequence (Lys/Arg-Cys-Pro-Val/Ile-Asp-His) repeated six times over an ~ 200 amino acid section of the protein that modulated DNA binding in response to heme (67). Then, in 1993, three copies of a similar sequence (Arg/Ser-Cys-Pro-Val/Ile-Leu-Ala) were identified by Lathrop

and Timko in the precursor protein sequence of both the nonspecific (ALAS1) and erythroid-specific (ALAS2) forms of δ -aminolevulinic acid synthase. Two copies are located in the presequence for mitochondrial translocation that is proteolytically removed on import to form the mature protein, and mutation of both Cys residues to Ser in those copies eliminated the heme-dependent inhibition of mitochondrial transport of mouse ALAS2 (52). Thus, the name “heme regulatory motif” was bestowed on the short sequence by the authors of the report, and they additionally noted the presence of HRMs in sequences of catalase and hemopexin. Two years later, Zhang and Guarente also referred to the short sequences in Hap-1 as HRMs and identified HRMs in heme-regulated eIF2 α kinase (HRI), heme lyase, and heme oxygenase-2 (HO2) (105).

The Zhang and Guarente report was much more defining to the field than simply cementing a name for the motif. First, an alignment of the sequences around the Cys-Pro dipeptide showed a tendency for a basic residue before the Cys and a hydrophobic residue after Pro (105), helping to define an HRM. Second, the report provided spectroscopic evidence of direct heme binding to a short peptide (Ala-Lys-Arg-Cys-Pro-Val-Asp-His-Thr-Met) corresponding to the consensus of the six HRMs of Hap-1 (105). Finally, based on mutational studies (Cys to Ala and Pro to Ala) of Hap-1, it was proposed that Cys acts as an axial ligand to Fe³⁺-heme and that Pro plays a structural role, possibly by exposing Cys for ligation (105). Thus, the study included several key factors in initially defining what an HRM is and how the motifs would be studied in the future.

The report also demonstrated that not all HRMs are created equal. The authors identified a seventh HRM (HRM7) in Hap-1 located near the activation domain closer to the C-terminus of the protein (the first six HRMs are located near the N-terminal DNA-binding domain) and demonstrated that it is HRM7 that modulates the activation of Hap-1 in response to heme (105), a finding that was confirmed by later studies that pointed to only a minor role of the other HRMs despite the ability of the peptide to bind heme (28, 33). Thus, given these findings on Hap-1 and ALAS2 demonstrating that HRMs even in the same protein can function differently, it became clear, and is one of the themes in this review, how important it is to characterize the function of the heme-binding event and to assess (as quantitatively as possible) heme binding to a designated HRM.

The functions assigned to HRMs

Assigning a function to a particular HRM is of great interest to those who study HRM-containing proteins. There does not appear to be one common function assignable to the HRMs—and it is believed that some HRMs have no functional relevance—so each HRM must be investigated thoroughly. Further, proteins that contain HRMs are varied, including transcription factors and enzymes involved in many different processes. Thus, the field includes a wide variety of approaches to study HRM-containing proteins, which has, in turn, led to the uncovering of a variety of effects of heme binding to an HRM (Fig. 1).

Despite a common function not having been assigned to HRMs, there are several examples of HRMs promoting heme-dependent protein degradation. The nuclear receptor (NR) Rev-erb β , which represses the transcription of genes involved in regulating circadian rhythms and is described in detail later, is degraded in a heme-dependent manner (9). Heme binding to human Period-2 targets the protein for degradation, likely through the ubiquitin-proteasome pathway, and prevents formation of the heterodimeric complex between period-2 and human cryptochrome 1 that is involved in the regulation of circadian rhythms (94). Heme binding to tumor suppressor protein and metabolic regulator, p53, interferes with the ability of the protein to interact with DNA (14) (Fig. 2) and facilitates its nuclear export for cytosolic degradation (79). Similarly, the ability of Bach1, which regulates the expression of heme oxygenase-1 (HO1), to bind to DNA is significantly decreased on heme binding, which also targets Bach1 for nuclear export, polyubiquitination, and

degradation (65, 82, 85, 103). *Bradyrhizobium japonicum* iron response regulator (Irr) regulates iron homeostasis and metabolism by acting as a repressor under low iron conditions and, under high iron conditions, is degraded on heme binding, allowing transcription to proceed (69, 97). Irr binds heme at both an HRM and a His-cluster site (His-His-His sequence) (39), and the protein appears to be degraded in a mechanism involving both sites that results in oxidative modification of the protein (46, 95, 96). ALAS1, the nonspecific form of δ -aminolevulinic acid synthase that catalyzes the first step of heme biosynthesis, contains three HRMs: two in the pre-sequence involved in mitochondrial import (HRM1 and HRM2) and one near the N-terminus of the mature protein (HRM3) (52). HRM1 and HRM3 of rat ALAS1 were shown through mutagenesis studies to be critical for the heme-dependent inhibition of mitochondrial import (63). In addition, HRM3 of human ALAS1 was recently shown to be required for the heme-dependent formation of an ALAS1/ClpXP complex as well as for the oxidative modification of ALAS1 that triggers recruitment of LONP1, an ATP-dependent protease (48). Heme-dependent degradation on heme binding to HRMs has also been proposed for iron regulatory protein 2 (IRP2), a regulator of iron metabolism (38), and arginyl-transferase, which conjugates arginine to the N-terminus of proteins as a part of the N-end rule of protein degradation (35).

In contrast to the examples provided earlier of HRMs participating in heme-dependent protein degradation are the HRM-containing proteins Hap-1 and HRI. Hap-1, briefly discussed earlier as one of the proteins in which HRMs were initially identified, activates the transcription of genes involved in respiration and the control of oxidative damage in yeast in response to heme. Heme binding to HRM7 of Hap-1 promotes the transition of a high-molecular-weight complex containing Hap-1 and several other proteins to a Hap-1 homodimer that binds DNA with a high affinity (106). Recently, it has been shown that Hap-1 represses transcription of its own gene and several others in the absence of heme (32, 34), making the HRM of Hap-1 an important sensor of heme levels in yeast. HRI also appears to be a sensor of intracellular heme levels. However, heme binding to HRI at an HRM promotes the transition from an active to an inactive state. It is when reticulocytes are heme deficient that HRI (without heme bound to the HRM) autophosphorylates and, subsequently, phosphorylates eIF2 α to downregulate protein synthesis, particularly globin synthesis (12, 37, 62).

In addition to the examples listed earlier, there are many more HRM-containing proteins in which the function of heme binding is unclear. For example, in contrast to what Lanthrop and Timko reported on the function of HRMs in mouse ALAS2 (52), a subsequent study showed no effect of heme on mitochondrial import of rat ALAS2 (63); thus, the relevance of the HRM is questioned. In addition, there are examples of proteins for which the function of the HRM remains elusive: HO2, which will be described in detail later; stanniocalcin-2, a glycoprotein shown to interact with HO1 (42); and DiGeorge critical region 8 (DGCR8), a protein involved in the first step of microRNA processing that appears to bind heme at a Pro-Cys (rather than Cys-Pro) site (19). Lastly, using a combinatorial peptide library approach, several other proteins were recently identified as having

FIG. 1. HRMs regulate the activity of enzymes, transcription factors, and an RNA regulatory protein. The modular structure of HRM-containing proteins is shown, along with the context and sequence of the HRMs. Domain organization (1–4) of IRP2 is based on its homology to aconitase (41, 74). Similarly, Irr is homologous to the Ferric Uptake Regulator (Fur) from *Pseudomonas aeruginosa*, and its domains are tentatively assigned as such; the N-terminal region of Irr that is distinct from Fur and contains the HRM is shown as a wavy line (29). The sequence of Rev-erbβ containing the HRM and redox-active Cys374 is shown; the A/B domain is hypervariable among members of the NR superfamily. For HO2, the sequence encompassing the heme ligand, His256 is shown in context to the nearby HRM. Hap-1 domain organization is based on functional studies (67); Act. refers to the domain that imparts transcription activation activity. NTD, or N-terminal domain of HRI is important for regulating quaternary structure (62). Delineation of domain boundaries are approximations. ALAS1, aminolevulinic acid synthase-1 nonspecific; Hap-1, heme activator protein-1; HO2, heme oxygenase isoform 2; HRM, heme regulatory motif; IRP2, iron regulatory protein 2; Irr, bacterial iron response regulator.

potential HRMs that may bind heme (6, 49, 50, 77). The authors used high-throughput screening to identify heme-binding peptides, and their sequences were then searched against protein sequence databases to identify proteins that may bind heme. Dipeptidyl peptidase 8 [(DP8), a member of the serine proteases (104)], FeoB [a bacterial ferrous iron transport protein (44)], and interleukin-36α [(IL-36α), a cytokine that induces inflammatory responses (21)] were, among other proteins, identified. The results suggest that not all HRM-containing proteins have even been identified, so the full extent of neither the capabilities of HRMs nor the

physiological links between heme levels and metabolic pathways is fully understood.

Heme binding to HRMs

A critical point in assigning a function to an HRM-containing protein is to show direct heme binding to the HRM. Providing evidence of this HRM-heme interaction subsequently eliminates the possibility of indirect heme regulation and, particularly in the case of proteins such as Hap-1 (105) and Bach1 (65) that contain multiple HRMs,

helps to distinguish responsive from unresponsive HRMs. Although X-ray crystal structures of only a few of the HRM-containing proteins (and their heme-bound forms) have been reported (Fig. 2), heme and heme-bound species lend themselves well to a variety of spectroscopic methods.

The classic model of the heme-HRM interaction includes Fe^{3+} of the heme in a penta-coordinated state with Cys acting an axial ligand. A shift in the absorbance of Fe^{3+} -heme in aqueous solution from ~ 385 nm to ~ 370 nm in the presence of the HRM-containing peptide or protein is characteristic of

Fe^{3+} -heme binding to an HRM in this manner (105). Such complexes have an electron paramagnetic resonance (EPR) signal at $g \sim 6$, although the signal is often broadened as compared with the signal for free Fe^{3+} -heme in solution (39, 77), as shown later in the UV-vis and EPR spectra of some specific HRMs. Other spectroscopic methods such as resonance Raman (39, 50, 77), electron nuclear double resonance (ENDOR) (2), extended X-ray absorption fine structure (EXAFS) (2), and X-ray absorption (XAS) (2) have demonstrated Cys ligation of heme at HRMs and assisted in the characterization of the heme-HRM interaction.

Structural data available for HRM-containing peptides and proteins provide insights into how heme binds at these sites. Chloroperoxidase (CPO) is a versatile enzyme that uses heme to catalyze a variety of oxidative reactions: halogenation, dehydrogenation (heme peroxidase-like activity), hydrogen peroxide decomposition (catalase-like activity), and oxygen insertion (cytochrome P450-like activity). The structure of CPO shows the heme bound within an 8-helix bundle; the proximal side resembles cytochrome P450 and provides an axial thiolate (cysteine) ligand, whereas the distal side contains polar residues that form the peroxide-binding site, like other peroxidases (Fig. 2) (84). The Cys ligand in CPO resides within an unusual Pro-Cys-Pro motif on a helix that is nearly perpendicular to the heme plane, and the two prolines position the Cys for ligation to the heme. The only access to the Fe^{3+} -heme is in the distal face, allowing only small organic substrates to interact with an iron-linked oxygen atom, accounting for its P450-like reaction. Another example of an HRM in a structured region is the Cys275-X-Cys277-Pro motif of the transcription factor, p53, which lies at the interface of the protein and its cognate DNA element (14) (Fig. 2). Cys277 of the HRM accepts a hydrogen bond from a nearby cytosine, but it is also responsible for binding heme

FIG. 2. HRMs provide unique structural determinants to proteins and enzymes. (A) The overall structure of chloroperoxidase (PDB: 2ciw) shows that the HRM and Fe^{3+} -heme cofactor are buried within the enzyme. A close-up view of the active site highlights the unique Pro-Cys-Pro HRM of CPO (prolines are shown as purple sticks, cysteine as yellow sticks), which positions the axial thiolate for heme ligation. Nonpolar residues within 4 Å of heme are shown as gray sticks. (B) p53, a transcription factor and tumor suppressor, is shown to be complexed with its cognate DNA promoter element (PDB: 1tsr). Residues flanking the HRM are shown as light gray cartoons to highlight the region, and a structural zinc atom is shown as a green sphere. (C) The NMR structure of an HRM-containing peptide from DP8 in complex with Ga^{3+} -PPIX. Left panel, the 15 structures of lowest target function are shown with the peptide backbone as blue sticks, the HRM Cys12 in yellow sticks, and Ga^{3+} -PPIX as red lines; the right panel depicts the inflexibility of the Cys-Pro core versus the side chains of surrounding residues. The structure serves as an excellent model demonstrating how the HRM Pro residue positions C-terminal residues away from heme, while poising the Cys-thiolate to act as a heme axial ligand. The structure of an IL-36 α -derived HRM peptide in complex with Ga^{3+} -PPIX recapitulates many of the features observed with the DP8 peptide (6). Figures in (C) are reprinted (adapted) with permission from Kühl *et al.* (50). Copyright (2013) American Chemical Society. CPO, chloroperoxidase; DP8, dipeptidyl peptidase 8; IL-36 α , interleukin-36 α ; NMR, nuclear magnetic resonance; PPIX, protoporphyrin IX.

along with neighboring C275 (14, 79). High heme levels drive binding to Cys275 and Cys277 and cause p53 dissociation from DNA, likely by disrupting the DNA:p53 hydrogen bond network.

In contrast, a number of HRMs are within disordered regions, as represented by the nuclear magnetic resonance (NMR) structures of two peptides spanning the HRM-containing regions of DP8 (Fig. 2) and IL-36 α (6, 50). UV-vis, EPR, and resonance Raman spectroscopies demonstrated that both a 23-mer peptide (SGGLPAPSDFKCPIKEEEIAITSG) spanning residues S495-G517 of DP8 and a 9-mer peptide (SEGGCPLIL) spanning the HRM of IL-36 α bound Fe³⁺-heme in a penta-coordinated state, with Cys acting as an axial ligand (6, 50, 77). Using gallium(III) protoporphyrin IX

(PPIX), a diamagnetic Fe³⁺-heme mimic (5), the authors were able to show that structural definition is introduced on Ga(III) PPIX binding only to the central amino acids around Cys and that Pro positions the Cys for axial ligation while positioning the C-terminal residues away from Ga(III) PPIX for both DP8 and IL-36 α peptides (6, 50). The surface binding of Ga(III) PPIX to the peptides, in contrast to the more structured and less solvent-exposed Fe³⁺-heme-binding pocket of CPO (Fig. 2), is consistent with HRMs being found in unstructured regions, such as in HO2 (2).

The HRM of Rev-erb β is also in a flexible unstructured loop, but, in contrast to the structures of CPO and the DP8 peptide, His and Cys act as axial ligands to Fe³⁺-heme (Fig. 3) (66). Although the structure will be discussed in greater detail

FIG. 3. Structural insight into HRM-mediated redox regulation of heme binding to nuclear receptor, Rev-erb β . (A) Structure of the Rev-erb β LBD in complex with Fe³⁺-heme (holo-LBD, PDB: 3cqv). Heme binds in a 6-coordinate, low-spin complex with His (H568, green sticks) and Cys (C384, yellow sticks) axial ligands. C384 and P385 (purple sticks) comprise an HRM core that resides on a flexible, unstructured loop. W402 (orange sticks) provides hydrophobic contacts to heme, and its fluorescence is quenched on heme binding (unpublished observations). (B) The Rev-erb β heme pocket is highly hydrophobic with nonpolar residues within 4 Å of heme shown as gray sticks (66). (C) Heme binding induces conformational changes of the LBD. Overlay of apo-LBD (dark red; PDB: 2v0v) and holo-LBD (light blue) structures aligned in Pymol; heme and the flexible HRM-harboring loop from the holo-LBD structure are omitted for clarity. The H3' helix swings out to accommodate the porphyrin ring, leading to a 11.2 Å shift of the W402 α -carbon. Further, conformational changes in helix 11 cause the τ -nitrogen of H568 to shift 8.0 Å, and assume its role as a Fe³⁺-heme ligand. (D) Pymol structural alignment of holo-LBD (light blue) versus apo-Rev-erb α LBD (dark green) in complex with an NCoR1 ID1 peptide (orange), PDB: 3n00; again, heme and the HRM loop are omitted for clarity. An anti-parallel beta sheet formed between an unraveled portion of Rev-erb α helix 11 and the NCoR1 peptide exhibits steric clash with helix H3' in the holo-LBD structure. Further, the heme axial ligand, H602 in Rev-erb α pivots away from the heme-binding pocket, suggesting that heme and NCoR1 would compete for different Rev-erb conformers. ID, interaction domain; LBD, ligand-binding domain; NCoR1, nuclear receptor compressor 1.

later, it demonstrates that Fe^{3+} -heme bound to HRMs can also be hexa-coordinated. In fact, a growing number of proteins have been shown to bind Fe^{3+} -heme at their HRM as a hexa-coordinated complex with Cys and an additional protein residue, usually His, acting as axial ligands. In addition to Rev-erb β , HRI (37, 62) and HO2 (20) also bind Fe^{3+} -heme with Cys and His ligands. These proteins have characteristic absorbance at ~ 420 nm and a low-spin rhombic EPR signal with g -values of 2.5, 2.3, and 1.9. Resonance Raman has also been shown to be useful in distinguishing penta- and hexa-coordination (39, 50).

Although spectroscopy may simplify the assignment of the ligands as Cys and His, actually identifying the His residue can be a challenge. In each of the three examples—Rev-erb β , HRI, and HO2—the His is located far outside of the Cys-Pro sequence motif of the HRM. Further, likely due to the surface binding of Fe^{3+} -heme to some HRMs rather than in a more defined binding pocket, Fe^{3+} -heme binds to some HRM-containing proteins in multiple conformations. For example, Fe^{3+} -heme bound to the HRM of Irr is in a mixture of penta- and hexa-coordinated states (39), complicating the assignment of ligands. A mixture of states was also observed for several peptides used in recent combinatorial peptide library studies (6, 49, 50, 77). For instance, an Fe^{3+} -heme-bound peptide, TPILCPFHL, based on the sequence of IRP2 displayed UV-vis absorbance, EPR, and resonance Raman spectra consistent with a mixture of penta- and hexa-coordinated Fe^{3+} -heme. The NMR structure of the Ga(III) PPIX-bound peptide is in the penta-coordinated state, but by the admission of the authors, there is insufficient distance between the Cys and His to form a hexa-coordinated species unless a second peptide were present (6). The histidine in this peptide corresponds to His204 in the protein, and this residue is not involved in Fe^{3+} -heme binding to Cys201 of the HRM. Rather, His204 is postulated to be necessary for protein degradation and the binding of Fe^{2+} -heme (38). Indeed, the spacing between the HRMs and the His residues that act as axial ligands in proteins such as Rev-erb β , HRI, and HO2 would be difficult to mimic with short peptides.

Although most of the HRMs that bind Fe^{3+} -heme in the hexa-coordinated state use Cys and His as axial ligands, one example of a protein that does not is DGCR8. As mentioned earlier, the sequence of the HRM of DGCR8 is Pro-Cys, rather than Cys-Pro. Spectroscopic studies have concluded that DGCR8 binds Fe^{3+} -heme with an unusual ligand arrangement of two Cys axial ligands (3). Fe^{3+} -heme is postulated to bind at a dimer interface with the Cys of an HRM from each monomer acting as an axial ligand. Two Cys ligands are not likely to be a common ligation environment for heme, but the example of DGCR8 is given here to emphasize that since not all HRM-containing proteins have been characterized, protein residues other than His can be the sixth ligand to hexa-coordinated Fe^{3+} -heme bound to HRMs.

HRMs and redox chemistry

This review focuses on Rev-erb β and HO2, which have been extensively studied in our laboratory, leading to characterization of the function and the various modes of heme binding to HRMs. In both Rev-erb β and HO2, the HRMs act as redox sensors in which the Cys residues form disulfide bonds, altering the affinity of the HRM for heme. Although

this has thus far only been noted for Rev-erb β and HO2, many HRM-containing proteins contain multiple HRMs and/or other Cys that may be available to form disulfide bonds. Therefore, by highlighting these two very different proteins, we hope to contribute to a more general understanding of HRMs and their potential link to the redox state of the cell.

Rev-Erb

Regulation of circadian rhythms by heme

Mammals are entrained to the diurnal cycle through light perception, a signal that is transduced *via* the optic nerve to the suprachiasmatic nucleus (SCN), a small region of the brain located at the optic chiasm (73, 76). Within the SCN, a set of core molecular clock proteins synchronize cellular processes through activation and repression of gene transcription. At the apex of the molecular clock are the *Bmal1* and *CLOCK* genes, whose protein products form a heterodimeric complex that binds to the promoters of clock-controlled genes to activate transcription. Among those genes activated are *Period 1*, *2*, and *3*, *Cryptochrome 1* and *2*, and *Rev-erb α* and *Rev-erb β* . *Period* (Per) and *Cryptochrome* (Cry) proteins form a complex that inhibits the activator function of Bmal1•CLOCK, whereas Rev-erbs repress the transcription of *Bmal1* and *CLOCK* genes. Together, Per, Cry, and Rev-erbs comprise the negative limb of the molecular clock that completes the feedback loop required for circadian rhythm maintenance (47).

The interplay of heme with the molecular clock is emerging as an important signaling axis. For example, heme biosynthesis and intracellular heme levels are entrained to the clock through regulation of ALAS1 by the Bmal1•NPAS2 (a forebrain *CLOCK* homolog) heterodimer (43). Significantly, NPAS2 is also a hemoprotein that binds carbon monoxide (CO), which further regulates its DNA-binding activity (17). On the negative limb of the circadian oscillator, Per2 contains an HRM that binds Fe^{3+} -heme and promotes its degradation (94). Further, *Per2* expression is regulated by p53, another HRM-containing transcription factor and metabolic regulator as discussed earlier (61). Rev-erb α and β isoforms also contain a redox-sensitive HRM that regulates heme binding, corepressor recruitment, and degradation (9, 11, 27). Because heme plays an integral role in energy production and metabolism, controlled degradation of Per2, Rev-erbs, and p53 through heme binding to their HRMs effectively couples those processes to the molecular clock. In the next section, we will discuss in detail the heme-dependent activities of Rev-erbs, and how they relate to circadian rhythm maintenance and entrainment of metabolic, inflammatory, and differentiation pathways.

Heme binding to Rev-erb α and Rev-erb β indirectly facilitates corepressor recruitment

Rev-erbs are transcription factors that belong to the NR superfamily, which includes receptors of thyroid, estrogen, and testosterone hormones. In the ligand-bound state, many NRs recruit transcription coactivator complexes with histone acetyltransferase activity that ultimately leads to target gene activation (25). Rev-erbs are unique to the superfamily in that they lack a structural determinant required for coactivator binding, rendering them as repressors of transcription (93). The α and β isoforms share >70% amino acid identity in their

DNA- and ligand-binding domains (LBD), and they are highly redundant in terms of circadian expression patterns and their target genes (8, 13, 18). Rev-erbs repress transcription either by direct competition for promoter elements with the transcription activator, RAR-related orphan receptor (ROR α), or by interacting with nuclear receptor corepressor (NCoR1) (1, 8, 13). NCoR1 is a 270 kDa protein that acts as a scaffold bringing together NRs and histone deacetylase complexes that enhance repression (40). As discussed earlier, Rev-erbs have been well studied in their role as circadian factors, but they also repress the transcription of key genes involved in glucose and lipid metabolism, inflammatory responses, differentiation, and body temperature regulation, entraining these processes to the clock (23, 24, 72, 88, 91, 102).

In 2007, two independent groups identified heme as the endogenous ligand for Rev-erbs (70, 102). Estimates of Rev-erb α/β affinity for Fe³⁺-heme using isothermal titration calorimetry (ITC) were between 0.35 and 3.52 μ M (59, 70). Diminution of cellular heme levels with the ALA-dehydratase inhibitor, succinylacetone, reversed Rev-erb α -dependent repression of target genes by disrupting the interaction of Rev-erb α with NCoR1 (70, 102). There is also evidence that heme binding to both α and β isoforms promotes their degradation likely through a ubiquitin-dependent pathway involving the E3-ligases, Arf-bp1, and Myc-bp2 (9, 51, 100). Based on these observations, a model was proposed in which Rev-erbs rapidly equilibrate with the regulatory heme (RH) pool so that when heme levels are high, Rev-erbs exist as holoproteins bound to NCoR1 and repress target gene transcription in a fine balance with their own degradation; controlling transcription output *via* degradation has also been observed with the thyroid hormone receptor (15). Presumably, low heme levels occlude binding to Rev-erbs based on the high K_d of the complex, leading to NCoR1 dissociation and relief of repression (Fig. 4). A potential problem with this model is that the apparent weak affinity for heme (μ M K_d) coupled with very low free (or exchangeable) cellular heme levels (<100 nM) would be inconsistent with the proposed (70) role of Rev-erbs as sensors of intracellular heme. The results of other *in vitro* studies indicated that the simple heme-based recruitment model was incomplete.

Despite congruity among the cellular results described earlier, structural and *in vitro* studies provided evidence contrary to the heme-dependent NCoR1 recruitment model. The structure of the Fe³⁺-heme•Rev-erb β complex shows heme bound in a six-coordinate system with axial ligands H568 and C384; the latter is provided by an HRM found on a flexible loop that is not present in the structure of the apo-protein (Fig. 3A, C) (66). The heme pocket is highly hydrophobic, stabilizing the nonpolar character of the porphyrin ring (Fig. 3B). Significant conformational changes are associated with heme binding to the apo-protein, namely a large shift of helix 3' that opens the pocket to accommodate heme, a pivot of H568 to assume its position as a heme axial ligand, and the appearance of the disordered HRM loop that provides C384 (Fig. 3C) (93). More importantly, comparing the structures of the Rev-erb β holoprotein to apoRev-erb α in complex with an NCoR1 peptide reveals a significant steric clash between helix 3 in the holoprotein structure and an anti-parallel beta sheet formed between helix 11 of Rev-erb α and the NCoR1 peptide (Fig. 3D) (68). The axial His residue, H602 in Rev-erb α , also swings out and away from the heme

pocket in the NCoR1 structure, suggesting that heme and NCoR1 would not bind simultaneously to the LBD. Several *in vitro* studies supported the structural data and demonstrated that heme and cobalt-PPIX effectively compete with NCoR1 peptides for binding to purified Rev-erb α/β LBDs (59, 70, 102).

A potential caveat to the structural and *in vitro* studies was the use of truncated Rev-erb α/β LBDs and NCoR1 peptides that may not accurately represent the interactions between full-length proteins. For instance, the C-terminus of NCoR1 contains three NR interaction domains (IDs), two of which are known to associate with Rev-erb α (45); thus, the use of a single ID peptide for binding and structural studies may not be sufficient to promote cooperative interactions between different IDs on a single polypeptide. Thus, it seemed likely that contacts among the Rev-erb N-terminus, DNA-binding domain, and hinge region may impart unique biochemical properties and heme-dependent activities unobservable in experiments utilizing isolated LBDs.

To discover whether the *in vitro* and cellular experiments would coincide if we used the full-length Rev-erb instead of the LBD alone, we developed strategies to purify full-length Rev-erb β (FLRev-erb β) and an NCoR1 construct (instead of the short peptide) containing all three IDs (9). First, we found through the use of electromobility shift assays and UV-vis spectroscopy that heme and NCoR1, indeed, form a ternary complex with Rev-erb β under equilibrium conditions, indicating the LBD is flexible in solution and can accommodate both ligands. However, heme was not required for the interaction of NCoR1 with the FLRev-erb β •DNA complex in a purified system and heme does not promote NCoR1 binding when present at stoichiometric levels with respect to Rev-erb β . In stark contrast to those results, heme is required for coimmunoprecipitation of endogenous NCoR1 from HEK 293 cell extracts with Rev-erb β . Further, wild-type recombinant FLRev-erb β co-precipitated with NCoR1, however a variant in which the His axial ligand is substituted with Phe (H568F), which exhibits a micromolar K_d for heme binding, is incapable of interacting with NCoR1. Similar results were previously observed with Rev-erb α and the cognate H602F variant, indicating that heme is essential for the interaction of both Rev-erb isoforms with NCoR1 (102). Thus, we hypothesize that an unidentified cellular component present in soluble extracts promotes the heme-dependent NCoR1 recruitment to Rev-erbs. Numerous candidates are worth investigating, especially those proteins shown to modulate Rev-erb α and β stability or repressor activity, including glycogen synthase kinase 3 β , which phosphorylates Rev-erb α promoting its stability (101); Tip60, an acetylase, and histone deacetylase 1 (HDAC1) that regulate Rev-erb β repressor activity by adding, or removing an acetyl group from an RXKK motif (90); and ZNHIT-1, a zinc-finger protein that interacts with Rev-erb β at the *apo-CIII* promoter, inhibiting its repressor activity (89). Heme-dependent interaction between any of these proteins and Rev-erb has not been investigated (Fig. 4).

An alternative hypothesis to explain the missing link between heme binding and NCoR1 recruitment is that diatomic gaseous signaling molecules, primarily nitric oxide (NO) and CO, could regulate Rev-erb α/β repressor activity. Both the truncated Rev-erb β LBD and FLRev-erb β bind CO with low nanomolar K_d s, but CO appears to have no effect on repressor

FIG. 4. Heme-dependent repression and degradation of Rev-erba/β. One mode of Rev-erba/β repression is through competition with RORα for binding to its response element (ROR-RE) within the promoters of target genes. Rev-erbs can bind as monomers and homodimers to Rev-REs, although recent studies suggest that they may also form heterodimers (8, 13, 31). Although Fe³⁺-heme binds to Rev-erbβ with high affinity ($K_d \leq 0.1$ nM), redox processes that cause dissociation of the Fe³⁺-heme axial thiolate ligand (including thiol-disulfide interconversion and Fe³⁺ to Fe²⁺-heme reduction) cause K_d to increase to ≥ 14 nM (11). Since the concentration of RH in the nucleus is ≤ 2.5 nM (30), loss of the HRM heme axial thiolate would cause dissociation of heme. Coimmunoprecipitation studies show that the NCoR1-HDAC3 complex has a high affinity for heme-bound Rev-erba/β (70, 102); once bound, the complex leads to target gene repression *via* histone deacetylation. Additional regulators of Rev-erbβ repressor activity have been identified, including Tip60, an acetyl transferase, HDAC1, a histone deacetylase, and ZNHIT-1, a zinc-finger containing protein; GSK3β has also been shown to regulate the stability of the α-isoform (see main text for references); whether heme plays a role in regulating interactions of these proteins with Rev-erbs is unknown. Gaseous signaling molecules, NO and CO may also regulate the repressor function of Rev-erbs by binding to heme; however, additional studies are required to support this hypothesis. Although heme facilitates interaction of NCoR1 with Rev-erbs, it also appears to promote proteasomal degradation of both isoforms through a ubiquitin-dependent pathway involving E3-ligases Arf-bp1 and Myc-bp2. CO, carbon monoxide; HDAC1, histone deacetylase 1; NO, nitric oxide; RH, regulatory heme; RORα, RAR-related orphan receptor α.

activity in a cellular system (9, 27, 66). NO, on the other hand, has been shown to inhibit Rev-erba/β repressor activity in cultured cells (66), but those results have yet to be validated *in vivo*, or the mechanistic details revealed. For example, does NO binding cause dissociation of NCoR1? What is the affinity of Fe²⁺-heme•Rev-erba/β for NO, and is that value consistent with the intracellular concentrations of NO? Does NO have secondary effects such as nitrosylation of Rev-erb zinc-finger thiolates as has been observed with other NRs (10)? In sum, additional studies are required to clarify the role, if any, of diatomic gases in Rev-erb regulation of target genes.

UV-vis spectrophotometric titrations revealed that Fe³⁺- and Fe²⁺-heme bind FLRev-erbβ with at least one order of magnitude higher affinity (low nanomolar K_d s) than those early estimates using ITC. Further, based on competition experiments, dissociation of Fe³⁺-heme from the FLRev-erbβ•heme complex was too slow to allow rapid equilibration of Rev-erbβ with RH (10^{-6} s⁻¹ = <1 day⁻¹), negating its role as a sensor of intracellular Fe³⁺-heme (9). If so, does the HRM serve any regulatory function other than to bind heme and poise the receptor for interaction with NCoR1? In the next section, we discuss results suggesting that Rev-erbs may exploit the redox properties of the HRM cysteine thiolate and

Fe³⁺-/Fe²⁺-heme couple to regulate heme affinity and corepressor recruitment.

Role of heme dissociation in redox signaling by Rev-erb β

Early biophysical studies of Rev-erb β described UV-vis, resonance Raman, EPR, and magnetic circular dichroism (MCD) spectra consistent with a low-spin 6-coordinate His/Cys ligated Fe³⁺-heme, as observed in the crystal structure shown in Figure 3A (58). However, reduction by dithionite to Fe²⁺-heme leads to dissociation of the C384 axial thiolate and its replacement by an exchangeable neutral ligand (Fig. 5). Since the loop containing the HRM is largely disordered and is not present in the structure of the apoprotein, we assume

that dissociation of C384 from heme would result in significant conformational changes. UV-vis equilibrium titrations suggested that Rev-erb β binds both Fe²⁺- and Fe³⁺-heme with similar low nanomolar affinity (9, 27). However, as discussed later, most equilibrium techniques vastly underestimate heme affinities and Fe²⁺-heme may not remain bound under the limiting heme concentrations in the cell. Several important questions require investigation to determine whether Fe³⁺/Fe²⁺-heme switching plays a role in regulating Rev-erb activity. For instance, what is the midpoint potential of the Fe³⁺/Fe²⁺-heme•Rev-erb couple, and what is the redox state of heme bound to Rev-erbs in the cell? Is the Fe³⁺/Fe²⁺-heme switch sensitive to changes in intracellular redox poise? If it is, what one-electron carrier or reductase is responsible for mediating Rev-erb α/β reduction?

Another potential redox switch regulating Rev-erb β repressor activity involves thiol-disulfide interconversion of the HRM cysteine. Under oxidizing conditions, C384 forms a disulfide bond with neighboring C374, causing an unidentified neutral ligand to assume the position of C384 in the Fe³⁺-heme complex (Fig. 5) (27). The K_d of the thiol-oxidized protein for Fe³⁺-heme (117 nM) is approximately five-fold higher than that for the thiol-reduced form (23 nM), suggesting that thiol-disulfide interplay could regulate Rev-erb β heme occupancy. Further, the switch occurs in *Escherichia coli* cells overproducing the Rev-erb β LBD, which exhibit a whole-cell EPR spectrum consistent with that of a thiol-reduced, six-coordinate low-spin Fe³⁺-heme; then, treatment of cells with the thiol oxidant, diamide, yields a spectrum indicative of a mixture of thiol-reduced/thiol-oxidized species. These data support the hypothesis that the Rev-erb β HRM is redox active and that the disulfide bond forms under oxidizing conditions. Future work should focus on whether the Rev-erb β thiol-disulfide rheostat occurs in mammalian cells in the context of the full-length protein and whether it interfaces with cellular redox buffers, for example, the glutathione:glutathione disulfide and dehydroascorbic acid:ascorbic

FIG. 5. Rev-erb β undergoes redox-mediated heme ligand switching. The thiol-reduced form of the Rev-erb β LBD (thiol-RED; C374 and C384 exist as thiols/thiolates) binds Fe³⁺-heme in 6C-LS complex with H568 and C384 axial ligands and a K_d of ~ 100 pM. Under oxidizing conditions, C384 forms a disulfide with neighboring C374 (thiol-OX), leading to a 6C-LS system where an unidentified neutral ligand assumes the position once occupied by the thiolate. Thiol-OX has a K_d for Fe³⁺-heme of ≥ 14 nM, well above the nuclear RH level of ≤ 2.5 nM, suggesting that thiol-OX would exist as an apoprotein in the nucleus. Our working hypothesis is that C374–C384 thiol-disulfide interconversion is in equilibrium with the GSH:GSSG or cysteine:cystine couples and reflects the redox poise of the nucleus. Similarly, the one-electron reduction of Fe³⁺ to Fe²⁺-heme is accompanied by dissociation of the HRM heme axial thiolate, leading to a mixed 5C-HS/6C-LS system where an unidentified neutral ligand (presumably the same ligand involved in the thiol-RED/OX ligand switch) is loosely associated with heme. Although it is unclear what heme redox state is relevant to Rev-erb β in the cell, it is intriguing to consider one-electron reductants that could interface with Rev-erb β , such as ferredoxins or cytochrome P450 reductase, although nuclear localization of the reductant is presumably required. 5C-HS, five-coordinate high spin; 6C-LS, six-coordinate low-spin.

acid systems that are under circadian control (92). Because Rev-erb α/β protein levels are tightly regulated by the transcription/translation feedback cycle of the molecular clock, redox regulation might represent an additional mechanism of controlling Rev-erb repressor activity.

Transient kinetic experiments support the hypothesis that the HRM in Rev-erb β is a redox sensor

A caveat of our early estimates of K_d for the Fe³⁺/Fe²⁺-heme complexes with FLRev-erb β and thiol-reduced/oxidized LBDs was the use of equilibrium titrations. Because K_d s for these complexes are in the low nanomolar range, UV-vis spectrophotometric titrations performed with micromolar concentrations of heme and protein yield typical, “dog-leg” curves that sharply saturate at 1:1 stoichiometry of heme and protein. Under such conditions, the concentration of free ligand cannot be assumed to equal the total concentration since most of the ligand is protein bound below a 1:1 ratio. The quadratic equation accounts for the concentrations of total *versus* free heme in such titrations but is limited in that the accuracy of the K_d is dependent on the sharpness of the curve; below a 10 nanomolar K_d , the standard error of the fit becomes rather large. To circumvent these issues, we used a kinetic approach, analyzing individual rate constants for the association (k_{on}) and dissociation (k_{off}) of heme and Rev-erb β , ultimately establishing accurate K_d s using the basic expression, $K_d = k_{off}/k_{on}$. As detailed in our recent manuscript (11), we utilized a unique buffer system containing caffeine, which has been shown to dissociate heme dimers and oligomers that usually complicate measurements of k_{on} using stopped-flow techniques because of their first-order, rate-limiting dissociation.

Heme association to Rev-erb β was complex and proceeded through several different kinetic steps. However, the initial binding phase, which made up >50% of total amplitude change, was hyperbolic with respect to protein concentration, indicative of a two-step binding mechanism (81). Similar hyperbolic dependence of k_{obs} on protein concentration has been observed in other heme:hemoprotein systems, suggesting that they have similar mechanisms of heme association (20, 54, 64). Interestingly, the k_{on} values for Fe³⁺-heme binding to wild-type protein, a C384A variant lacking the HRM cysteine thiolate, and the thiol-oxidized form were between $3.6 \times 10^5 M^{-1} s^{-1}$ and $4.1 \times 10^5 M^{-1} s^{-1}$, indicating that loss of the axial thiolate has a negligible influence on heme binding. Fe²⁺-heme association, however, proceeded with a second-order rate constant of $k_{on} = 2.7 \times 10^9 M^{-1} s^{-1}$, demonstrating that the heme redox state is an important determinant of k_{on} .

The measurement of k_{on} was relatively straightforward, whereas heme dissociation was biphasic, that is, affording two k_{off} values. For these experiments, one follows heme dissociation from Rev-erb β by monitoring formation of the complex between heme and the H64Y/V68F myoglobin variant, which exhibits a unique UV-vis spectrum. For wild-type Rev-erb β , off-rates were between 10^{-4} – $10^{-5} s^{-1}$, with a K_d range of 104–639 pM; the slow kinetic phase predominated and made up >80% of the total amplitude, indicating that most of the bound heme dissociates with a K_d of ~ 100 pM. In contrast, the Fe³⁺-heme off-rates from thiol-oxidized and C384A proteins were between 10^{-2} and $10^{-3} s^{-1}$,

giving K_d ranges of 14–50 nM and 4–32 nM, respectively. Further, the k_{off} values of Fe²⁺-heme from wild-type protein were $1.4 s^{-1}$ – $6.5 \times 10^{-2} s^{-1}$, yielding a K_d range of 24–519 nM. Thus, dissociation of the axial thiolate *via* either redox process (oxidation of the HRM thiolate to a disulfide or heme reduction) significantly lowers Rev-erb β heme affinity. In other words, Rev-erb β exhibits features of a redox sensor rather than a direct heme sensor. This hypothesis gains momentum given coimmunoprecipitation results demonstrating that the C384A variant of FLRev-erb β loses >70% NCoR1 binding capacity with respect to wild-type protein, corroborating the importance of the HRM cysteine in stabilizing both heme and NCoR1 interactions.

These redox sensor-related results take on an even greater impact in the context with recent work by Reddi and colleagues describing the accurate determination of intracellular RH levels in *Saccharomyces cerevisiae* (30). In that study, fluorescent heme sensors were targeted to different subcellular organelles and RH levels were determined by using elegant normalization techniques that defined fluorescence emission ratios (with respect to an internal fluorescence standard) of the sensors in heme-free and heme-replete conditions. RH in the cytosol was found to be 20–40 nM, whereas heme levels are kept at a minimum (<2.5 nM) in the mitochondria and nucleus. RH in the nucleus and mitochondria is likely maintained at these extremely low levels to limit the amount of free heme available to participate in Fenton reactions, leading to damaged DNA or respiratory chain elements. A complicating factor is that the heme sensor employed is insensitive to Fe³⁺-heme at the low concentrations present in the cell; thus, the aforementioned values are reflective of the Fe²⁺-heme RH pool, although Fe³⁺-heme RH is also likely to exist due to varying ligand conformations with glutathione or protein side chains in the cellular milieu. In any case, those values provided in the aforementioned study lay the groundwork for discussions on the likelihood of heme:protein interactions with an RH pool in the low nanomolar range. Since the majority of the thiol-reduced, wild-type Rev-erb β population binds Fe³⁺-heme with a K_d of 0.1 nM, it would predominantly exist as holoprotein with <2.5 nM RH in the nucleus. However, thiol oxidation or heme reduction drives the K_d above 14 nM. Because these values lie on the upper end of the RH estimation, Rev-erb β may exist as an apoprotein under those conditions. Another hypothesis is that Rev-erbs might bind Fe²⁺-heme after being translated in the cytosol, with heme then oxidizing to Fe³⁺-heme to “lock in” a particular conformation of the protein. Regardless of this, the initial estimates of Rev-erb α/β affinity of 0.35–3.52 μM with ITC are problematic in that they suggest the protein would exist within the cell in the apo form exclusively (59, 70). Our results underscore the importance of using highly sensitive spectroscopic and kinetic studies to investigate the molecular mechanism of heme-dependent NCoR1 recruitment, and the possibility of Rev-erbs acting as redox sensors either through the Fe³⁺/Fe²⁺-heme or the thiol-disulfide couple (11).

Heme Oxygenase-2

HO2 is an HRM-containing protein

A variety of mechanisms are involved in the regulation of heme homeostasis to ensure that heme levels are maintained

at concentrations that are high enough for cellular processes but low enough to avoid the cytotoxic effects of heme. One such mechanism involves heme degradation, a pathway in which heme is converted to biliverdin, and biliverdin is, subsequently, converted to the more readily excreted product bilirubin (55). The first step is rate limiting and is catalyzed by HO, the only enzyme in mammals known to degrade heme.

HO2, one of the two major isoforms of HO identified in mammals, contains three HRMs (Fig. 1). One HRM, centered at Cys127-Pro128 in human HO2, is located in the α -helical catalytic core region, consisting of residues 28–248 where heme binds and undergoes conversion to biliverdin. The other two HRMs, centered at Cys265-Pro266 and Cys282-Pro283, are located in an unstructured region of the protein between the catalytic core and the membrane-spanning region that tethers the protein to the endoplasmic reticulum. HO2 was among the proteins first identified as having an HRM (105), and it was immediately thereafter noted that the presence of HRMs in HO2 distinguished it from HO1, which contains no cysteines (60). HO1 is an inducible protein expressed in most tissues but with particularly high levels in the liver and spleen, whereas HO2 is constitutively expressed and has been primarily identified in the brain and testes (55). However, the two proteins convert heme to biliverdin with similar catalytic efficiencies (56) and share a high level of homology (55% identical and 76% similar for the human proteins). A comparison of the structures of HO2 and HO1 illustrates how similar the two proteins are in the catalytic core region, consisting of residues 1–230 in human HO1 (4, 78). However, the HO2 and HO1 sequences diverge significantly between the catalytic core and the membrane-spanning region where the HRMs of HO2 are located, a region for which there is little structural information. As the HRMs appear to be the major difference between the two proteins, attention has been given to the heme-binding properties and the function of the HRMs of HO2 in an effort to understand why nature has selected a new form of HO that catalyzes the same reaction with a similar catalytic efficiency as the ancient form (HO1).

Heme binding to the HRMs of HO2

To infer that any differences between HO2 and HO1 are linked to the presence of HRMs in HO2, heme binding to the HRMs needed to be confirmed. An initial study of rat HO2 (60) demonstrated that adding heme to a 10-mer peptide spanning one of the HRMs (Val-Arg-Lys-Cys₂₆₄-Pro-Phe-Tyr-Ala-Ala-Gln) results in a dramatic color change, suggesting heme ligation. A more subtle color change was observed for a peptide spanning the other C-terminal HRM (Gly-Ser-Asn-Cys₂₈₁-Pro-Phe-Arg-Thr-Ala-Met). Further, subtle differences in the absorbance spectra of a Cys264Ala/Cys281Ala variant of rat HO2 as compared with the wild-type led to the hypothesis that the wild-type was binding ~2 more equivalents of heme per monomer of protein than the variant, suggesting that the HRMs were involved in binding heme independently of heme binding to the catalytic core (60). The results were slightly ambiguous but enough to pique the curiosity of others.

A significant finding in the further characterization of the HRMs was the discovery of a disulfide bond involving the

cysteines in the HRMs of the soluble form of human HO2 (HO2_{sol}), which spans residues 1–288, thus eliminating residues 289–316, which form the membrane-spanning region. Cys265 and Cys282 were shown to form a disulfide bond by the 5,5'-dithiobis(nitrobenzoic acid) (DTNB) assay and by monitoring alkylation of the cysteine residues using mass spectrometry (99). A later study using ¹³C-Cys-labeled HO2_{sol} and two-dimensional NMR also confirmed disulfide bond formation (86). Further, through thiol trapping experiments using the isotope-coded affinity tag technique (53), the thiols were shown to be 60–70% reduced *in vivo* under normal growth conditions (98). The dithiol/disulfide ratio also changed to reflect changes in the cellular redox state, with 81–87% of thiols reduced under reducing conditions and 86–89% of thiols in the disulfide state under oxidizing conditions. The midpoint potential for the thiol/disulfide conversion, measured by thiol trapping and fluorescence trapping, was calculated to be –200 mV, which is near the ambient cellular redox potential (71). Thus, the thiol/disulfide conversion appears to be physiologically relevant and to link HO2 to the cellular redox state.

The added significance of the thiol/disulfide conversion in HO2 is that a disulfide bond necessarily limits the ability of Cys265 and Cys282 to coordinate Fe³⁺-heme. Indeed, no thiol coordination of Fe³⁺-heme was observed with fully oxidized (disulfide state) as-purified HO2_{sol} (99), and its spectral features were identical to those of a truncated form of HO2 (HO2_{core}), which spans residues 1–248 and lacks the C-terminal HRMs (20, 99). Titration of oxidized HO2_{sol} (HO2_{sol}^O) or HO2_{core} with Fe³⁺-heme resulted in an increase at 406 nm that saturated at 1:1 protein to Fe³⁺-heme and an EPR signal (signal X) with *g* values at 2.87, 2.26, and 1.99 (Fig. 6). These results are consistent with His/aquo axial ligation to the Fe³⁺-heme in the catalytic core, including the imidazole of a conserved His (His45 in human HO2) and a solvent water, which interacts with a glycine-rich helix (4).

Surprisingly, on reduction of the disulfide bond of HO2 and subsequent incubation with Fe³⁺-heme, the EPR spectrum of HO2_{sol}^R (reduced HO2_{sol}) included both signal X and a second signal (signal Y) with *g* values at 2.41, 2.26, and 1.91, which are characteristic of six-coordinate Fe³⁺-heme with Cys/His ligation (20, 99) (Fig. 6). Thiol ligation had never been observed for any form of HO and is a feature characteristic of an entirely different class of hemoproteins, for example, cytochrome P₄₅₀ (26) and some regulatory hemoproteins (37, 71). Various results in different groups indicated that only one heme was bound per HO2 monomer (86, 99). Thus, to account for signal Y, a “fishhook” mechanism was initially proposed in which a Cys from an HRM (likely Cys265 based on mutational studies) displaces an axial ligand at Fe³⁺-heme bound to the catalytic site on reduction of the disulfide bond, resulting in His45/Cys265 ligation of Fe³⁺-heme (99). However, problems with this proposal began to mount, favoring a model (Fig. 6D) in which Fe³⁺-heme binding to Cys residues in the HRMs is independent of binding to His45 at the catalytic core (20). For example, signal Y was observed in forms of HO2 in which His45 is not available to ligate heme, as in, the His45Ala variant of HO2_{sol}^R and HO2 in the disulfide bond-reduced form, spanning residues 213–288 (HO2_{tail}^R), which lacks the heme-binding site in the catalytic core (20). Rather, ¹⁴N and ¹⁵N Davies ENDOR spectroscopic experiments showed that

FIG. 6. Spectral characterization of HO2 in the Fe³⁺-heme-bound forms. (A) Absorbance spectra of 5 μ M Fe³⁺-heme-bound forms of HO2_{core} (···), HO2_{tail}^R (---), and HO2_{sol}^R (—) in 50 mM Tris (pH 8.0) and 50 mM KCl at 20°C. (B) EPR spectra of the Fe³⁺-heme-bound forms of HO2_{core}, HO2_{sol}^R, HO2_{tail}^R, and the His45Ala variant of HO2_{sol}^R. The *g* values are indicated above the spectra. (C) Absorbance spectra of 5 μ M Fe³⁺-heme-bound forms of HO2_{tail}^R (—), HO2_{tail}(C282A)^R (---), and HO2_{tail}(C265A)^R (···) in 50 mM Tris (pH 8.0) and 50 mM KCl at 20°C. (D) A model of heme binding to the oxidized form of HO2_{sol}, which has a single heme-binding site due to the participation of Cys265 and Cys282 in a disulfide bond, and the reduced form of HO2_{sol}, which has three heme-binding sites. Below each heme-binding site are the characteristics of that site, including the maximum absorbance, the *g*-values, the *K_d* values obtained by equilibrium titrations [*K_d* (equil)], and the *k_{off}*/*k_{on}* values obtained by kinetic measurements. The figures in (A–C) are reprinted (adapted) with permission from Fleischhacker *et al.* (20). Copyright (2015) American Chemical Society. EPR, electron paramagnetic resonance; HO2_{core}, HO2 spanning residues 1–248; HO2^R, HO2 in the disulfide bond-reduced form; HO2_{sol}, HO2 spanning residues 1–288; HO2_{tail}, HO2 spanning residues 213–288.

His256 is an axial ligand to the heme giving rise to signal Y (20). Indeed, the absorbance spectra of the Fe³⁺-heme-bound forms of HO2_{tail}^R and HO2_{core} could account for all of the features observed for HO2_{sol}^R (Fig. 6A, B); for example, the absorbance band at 422 nm is typical for Cys/His ligated Fe³⁺-heme (37, 58, 62) and could be assigned to Cys265/His256 ligation (as well as accounting for the shoulder in the spectrum of HO2_{sol}^R), whereas the broad band at 368 nm could be assigned to the Cys282 site (20, 105). Quantification of Fe³⁺-heme bound to the various HO2 forms by pyridine hemochrome assay (20) also demonstrated that the thiol-reduced HO2 has three independent Fe³⁺-heme-binding sites.

Various spectroscopic techniques were used to probe for the thiol-coordinated Fe³⁺-heme in HO2. MCD spectra of

Fe³⁺-heme-bound human HO2 and the Cys variants suggested that a six-coordinate, Cys265-ligated Fe³⁺-heme is formed as a minor species on reduction of the disulfide bond (22); Fe K-edge EXAFS and XAS data supported thiol coordination by both Cys265 and Cys282, although Cys265 appeared to bind with a somewhat higher affinity than Cys282 to the Fe³⁺ center (2); and ¹H and ¹³C ENDOR experiments using reduced, Fe³⁺-heme-bound HO2 that had been ²H-Cys or ¹³C-Cys labeled conclusively demonstrated Fe³⁺-heme coordination at the HRMs (2). Thus, collectively these various lines of enquiry unambiguously showed that the reduced state of HO2 contains three hemes (Fig. 6D): one at the catalytic core (His45/aquo) and two additional heme-binding sites at the C-terminal HRMs: Cys265/His256 and Cys282. Regardless of

this, one study proposed that the HRMs of HO2 do not stably coordinate to Fe^{3+} -heme (86); however, in that study involving equilibrium titrations, Fe^{3+} -heme was added to HO2 in the presence of excess tris(2-carboxyethyl)phosphine, and phosphines are reasonably strong Fe^{3+} -heme ligands (57, 75, 83).

Kinetics of heme binding to HO2

Spectral data suggested that the three binding sites of HO2 had varying affinities for Fe^{3+} -heme. At less than saturating concentrations of Fe^{3+} -heme, the spectra were dominated by features associated with Fe^{3+} -heme binding at the His45/aquo site, suggesting that the catalytic core had a higher affinity for Fe^{3+} -heme than the HRMs. Further, Fe K-edge EXAFS and XANES data suggested that Cys265 had a higher affinity for Fe^{3+} -heme than Cys282 (2). However, Fe^{3+} -heme K_d values were difficult to ascertain from equilibrium titrations of $\text{HO2}_{\text{sol}}^{\text{R}}$ due to the complexity of the UV-vis spectra. Thus, equilibrium titrations of the truncated forms of HO2 were performed and revealed K_d values of 14 nM for HO2_{core} (Fe^{3+} -heme binding to the His45/aquo site), 90 nM for $\text{HO2}_{\text{tail}}(\text{C282A})^{\text{R}}$ (Cys265/His256 site), and 900 nM for $\text{HO2}_{\text{tail}}(\text{C265A})^{\text{R}}$ (Cys282 site) (20), confirming that the three sites have varying affinities for Fe^{3+} -heme.

However, as discussed earlier for Rev-erb β , equilibrium titrations may not give the most accurate K_d values. Instead, individual rate constants for the association (k_{on}) and dissociation (k_{off}) of Fe^{3+} -heme provided a more detailed view of binding. Further, this kinetic approach permitted the observation of Fe^{3+} -heme binding to some of the sites in $\text{HO2}_{\text{sol}}^{\text{R}}$. The rate constants were very similar for the sites in the truncated proteins as the comparable site in $\text{HO2}_{\text{sol}}^{\text{R}}$, indicating that the truncated proteins are good models for the full-length protein. Calculation of K_d values using the simple equation $K_d = k_{\text{off}}/k_{\text{on}}$ revealed K_d values of 0.08–0.2 nM for Fe^{3+} -heme binding to the His45/aquo site and 0.3–0.4 nM for Fe^{3+} -heme binding to the Cys265/His256 site (20). The k_{on} value could not be determined for Fe^{3+} -heme binding to the Cys282 site, but estimates would suggest a value of ~ 1 nM. Values obtained by kinetic measurements follow the same trend as equilibrium titrations, that is, the His45/aquo site has a higher affinity than Cys265/His256, which, in turn, has a higher affinity than Cys282. However, the lower K_d values are on par with RH levels in the cell, in contrast to the values obtained by equilibrium titrations that would have suggested that the HRMs only bind Fe^{3+} -heme under conditions in which heme levels were elevated. Therefore, the redox state of the cell, by influencing the thiol/disulfide conversion of Cys265 and Cys282, appears to be more relevant to Fe^{3+} -heme binding to the HRMs of HO2 than previously thought, suggesting that the HRMs function as redox sensors.

Functional significance of HRMs in HO2

HRMs appear to place HO2 in a unique position at which the redox state of the cell and regulation of heme and iron homeostasis intersect. However, the exact nature of their function remains unclear. Repeated experiments have demonstrated that the steady-state activity of HO2 is not affected by substitution of any of the Cys to Ala or by exclusion of the cysteine residues by truncation of the protein (16, 20, 60, 99). A more detailed investigation of heme hydroxylation, the initial steps in heme degradation, by HO2 using a combina-

tion of radiolytic cryoreduction/annealing with UV-vis and EPR spectroscopy demonstrates that there is no involvement of the HRMs in the catalytic cycle of HO2 (16). In addition, the HRMs can bind but not oxidize heme as no steady-state activity was observed with $\text{HO2}_{\text{tail}}^{\text{R}}$ (16). HO2 and HO1 also appear to bind cytochrome P450 reductase, which provides electrons for the HO reaction, with the same corresponding residues (80), further suggesting that the degradation of heme proceeds in the catalytic core independently of the HRMs. HRMs are also not involved in the specific activation of HO2 by menadione analogs or its specific inhibition by clemizole analogs (87) nor do they participate in binding of the heme mimic Zn(II) PPIX, an HO inhibitor (36). Thus, further investigation is needed to detail the functional significance of heme binding to HRMs in a redox-regulated manner.

Conclusions and Future Directions

Here, we have highlighted HO2 and Rev-erb β to illustrate the similarities and differences between two hemoproteins that both contain HRMs. HRMs of both proteins appear to act as redox sensors in that the participation of the HRM cysteine(s) in a thiol/disulfide switch alters affinity for heme. Therefore, future studies of HRM-containing proteins should include experiments that probe for disulfide bonds and/or differences in heme binding under oxidizing and reducing conditions. HRMs acting as redox sensors may be applicable to other HRM-containing proteins as many contain multiple HRMs and/or other cysteine residues. Further, the affinity for heme at the HRMs, based on the kinetic approach used for HO2 and Rev-erb β , may be lower than previously proposed, suggesting that the functional significance of the HRMs may be greater than expected. The survey of HRM-containing proteins (see the Introduction section and Fig. 1) indicates that HRMs play a role in regulating protein stability in a significant number of proteins, many of which are involved in regulating circadian rhythm and metabolic pathways (Rev-erbs, p53, and Per2), suggesting that it may be advisable to probe more HRMs for this function. Thus, the study of HRMs, in general, is a growing field with many interesting questions yet to be answered.

Acknowledgments

This work has been funded by NIH (R21HL089837, R01-GM123513, and R01-HL102662A) to SWR, F32HL114150 to ELC and by the University of Michigan Biomedical Research Council (to SWR).

References

1. Akashi M and Takumi T. The orphan nuclear receptor ROR α regulates circadian transcription of the mammalian core-clock *Bmal1*. *Nat Struct Mol Biol* 12: 441–448, 2005.
2. Bagai I, Sarangi R, Fleischhacker AS, Sharma A, Hoffman BM, Zuiderweg ERP, and Ragsdale SW. Spectroscopic studies reveal that the heme regulatory motifs of heme oxygenase-2 are dynamically disordered and exhibit redox-dependent interaction with heme. *Biochemistry* 54: 2693–2708, 2015.
3. Barr I, Smith AT, Senturia R, Chen YQ, Scheidemantle BD, Burstyn JN, and Guo F. DiGeorge critical region 8 (DGCR8) is a double-cysteine-ligated heme protein. *J Biol Chem* 286: 16716–16725, 2011.

4. Bianchetti CM, Yi L, Ragsdale SW, and Phillips GN, Jr. Comparison of apo- and heme-bound crystal structures of a truncated human heme oxygenase-2. *J Biol Chem* 282: 37624–37631, 2007.
5. Bohle DS, Dodd EL, Pinter TBJ, and Stillman MJ. Soluble diamagnetic model for malaria pigment: coordination chemistry of gallium(III)protoporphyrin-IX. *Inorg Chem* 51: 10747–10761, 2012.
6. Brewitz HH, Köhl T, Goradia N, Galler K, Popp J, Neugebauer U, Ohlenschläger O, and Imhof D. Role of the chemical environment beyond the coordination site: structural insight into Fe-III protoporphyrin binding to cysteine-based heme-regulatory protein motifs. *Chem-biochem* 16: 2216–2224, 2015.
7. This reference has been deleted.
8. Bugge A, Feng D, Everett LJ, Briggs ER, Mullican SE, Wang F, Jager J, and Lazar MA. Rev-erb α and Rev-erb β coordinately protect the circadian clock and normal metabolic function. *Genes Dev* 26: 657–667, 2012.
9. Carter EL, Gupta N, and Ragsdale SW. High affinity heme binding to a heme regulatory motif on the nuclear receptor Rev-erb β leads to its degradation and indirectly regulates its interaction with nuclear receptor corepressor. *J Biol Chem* 291: 2196–2222, 2016.
10. Carter EL and Ragsdale SW. Modulation of nuclear receptor function by cellular redox poise. *J Inorg Biochem* 133: 92–103, 2014.
11. Carter EL, Ramirez Y, and Ragsdale SW. The heme-regulatory motif of nuclear receptor Rev-erb β is a key mediator of heme and redox signaling in circadian rhythm maintenance and metabolism. *J Biol Chem* 292: 11280–11299, 2017.
12. Chen JJ and London IM. Regulation of protein-synthesis by heme-regulated EIF-2 α kinase. *Trends Biochem Sci* 20: 105–108, 1995.
13. Cho H, Zhao X, Hatori M, Yu RT, Barish GD, Lam MT, Chong L-W, DiTacchio L, Atkins AR, Glass CK, Liddle C, Auwerx J, Downes M, Panda S, and Evans RM. Regulation of circadian behaviour and metabolism by REV-ERB- α and REV-ERB- β . *Nature* 485: 123–127, 2012.
14. Cho Y, Gorina S, Jeffrey P, and Pavletich N. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. *Science* 265: 346–355, 1994.
15. Dace A, Zhao L, Park KS, Furuno T, Takamura N, Nakanishi M, West BL, Hanover JA, and Cheng S-Y. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. *Proc Natl Acad Sci U S A* 97: 8985–8990, 2000.
16. Davydov R, Fleischhacker AS, Bagai I, Hoffman BM, and Ragsdale SW. Comparison of the mechanisms of heme hydroxylation by heme oxygenases-1 and-2: kinetic and cryoreduction studies. *Biochemistry* 55: 62–68, 2016.
17. Dioum EM, Rutter J, Tuckerman JR, Gonzalez G, Gilles-Gonzalez M-A, and McKnight SL. NPAS2: a gas-responsive transcription factor. *Science* 298: 2385–2387, 2002.
18. Dumas B, Harding HP, Choi HS, Lehmann KA, Chung M, Lazar MA, and Moore DD. A new orphan member of the nuclear hormone receptor superfamily closely related to Rev-Erb. *Mol Endocrinol* 8: 996–1005, 1994.
19. Faller M, Matsunaga M, Yin S, Loo JA, and Guo F. Heme is involved in microRNA processing. *Nat Struct Mol Biol* 14: 23–29, 2007.
20. Fleischhacker AS, Sharma A, Choi M, Spencer AM, Bagai I, Hoffman BM, and Ragsdale SW. The C-terminal heme regulatory motifs of heme oxygenase-2 are redox-regulated heme binding sites. *Biochemistry* 54: 2709–2718, 2015.
21. Gabay C and Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions. *J Leukoc Biol* 97: 645–652, 2015.
22. Gardner JD, Yi L, Ragsdale SW, and Brunold TC. Spectroscopic insights into axial ligation and active-site H-bonding in substrate-bound human heme oxygenase-2. *J Biol Inorg Chem* 15: 1117–1127, 2010.
23. Gerhart-Hines Z, Feng D, Emmett MJ, Everett LJ, Loro E, Briggs ER, Bugge A, Hou C, Ferrara C, Seale P, Pryma DA, Khurana TS, and Lazar MA. The nuclear receptor Rev-erb α controls circadian thermogenic plasticity. *Nature* 503: 410–413, 2013.
24. Gibbs JE, Blaikley J, Beesley S, Matthews L, Simpson KD, Boyce SH, Farrow SN, Else KJ, Singh D, Ray DW, and Loudon ASI. The nuclear receptor REV-ERB α mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines. *Proc Natl Acad Sci U S A* 109: 582–587, 2012.
25. Glass CK and Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. *Genes Dev* 14: 121–141, 2000.
26. Guengerich FP. New trends in cytochrome P450 research at the half-century mark. *J Biol Chem* 288: 17063–17064, 2013.
27. Gupta N and Ragsdale SW. Thiol-disulfide redox dependence of heme binding and heme ligand switching in nuclear hormone receptor Rev-erb β . *J Biol Chem* 286: 4392–4403, 2011.
28. Hach A, Hon T, and Zhang L. A new class of repression modules is critical for heme regulation of the yeast transcriptional activator Hap1. *Mol Cell Biol* 19: 4324–4333, 1999.
29. Hamza I, Chauhan S, Hassett R, and O'Brian MR. The bacterial Irr protein is required for coordination of heme biosynthesis with iron availability. *J Biol Chem* 273: 21669–21674, 1998.
30. Hanna DA, Harvey RM, Martinez-Guzman O, Yuan X, Chandrasekharan B, Raju G, Outten FW, Hamza I, and Reddi AR. Heme dynamics and trafficking factors revealed by genetically encoded fluorescent heme sensors. *Proc Natl Acad Sci U S A* 113: 7539–7544, 2016.
31. Harding HP and Lazar MA. The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat. *Mol Cell Biol* 15: 4791–4802, 1995.
32. Hickman MJ and Winston F. Heme levels switch the function of Hap1 of *Saccharomyces cerevisiae* between transcriptional activator and transcriptional repressor. *Mol Cell Biol* 27: 7414–7424, 2007.
33. Hon T, Hach A, Lee HC, Cheng T, and Zhang L. Functional analysis of heme regulatory elements of the transcriptional activator Hap1. *Biochem Biophys Res Commun* 273: 584–591, 2000.
34. Hon T, Lee HC, Hu ZZ, Iyer VR, and Zhang L. The heme activator protein Hap1 represses transcription by a heme-independent mechanism in *Saccharomyces cerevisiae*. *Genetics* 169: 1343–1352, 2005.
35. Hu RG, Wang HQ, Xia ZX, and Varshavsky A. The N-end rule pathway is a sensor of heme. *Proc Natl Acad Sci U S A* 105: 76–81, 2008.

36. Huang TJ, McCoubrey WK, and Maines MD. Heme oxygenase-2 interaction with metalloporphyrins: function of heme regulatory motifs. *Antioxid Redox Signal* 3: 685–696, 2001.
37. Igarashi J, Sato A, Kitagawa T, Yoshimura T, Yamauchi S, Sagami I, and Shimizu T. Activation of heme-regulated eukaryotic initiation factor 2 α kinase by nitric oxide is induced by the formation of a five-coordinate NO-heme complex: optical absorption, electron spin resonance, and resonance Raman spectral studies. *J Biol Chem* 279: 15752–15762, 2004.
38. Ishikawa H, Kato M, Hori H, Ishimori K, Kirisako T, Tokunaga F, and Iwai K. Involvement of heme regulatory motif in heme-mediated ubiquitination and degradation of IRP2. *Mol Cell* 19: 171–181, 2005.
39. Ishikawa H, Nakagaki M, Bamba A, Uchida T, Hori H, O'Brian MR, Iwai K, and Ishimori K. Unusual heme binding in the bacterial iron response regulator protein: spectral characterization of heme binding to the heme regulatory motif. *Biochemistry* 50: 1016–1022, 2011.
40. Ishizuka T and Lazar MA. The N-CoR/histone deacetylase 3 complex is required for repression by thyroid hormone receptor. *Mol Cell Biol* 23: 5122–5131, 2003.
41. Iwai K, Klausner RD, and Rouault TA. Requirements for iron-regulated degradation of the RNA binding protein, iron regulatory protein 2. *EMBO J* 14: 5350–5357, 1995.
42. Jiang J, Westberg JA, and Andersson LC. Stanniocalcin 2, forms a complex with heme oxygenase 1, binds heme and is a heat shock protein. *Biochem Biophys Res Commun* 421: 274–279, 2012.
43. Kaasik K and Chi Lee C. Reciprocal regulation of haem biosynthesis and the circadian clock in mammals. *Nature* 430: 467–471, 2004.
44. Kammler M, Schon C, and Hantke K. Characterization of the ferrous iron uptake system of *Escherichia coli*. *J Bacteriol* 175: 6212–6219, 1993.
45. Kim JY, Son YL, Kim J-S, and Lee YC. Molecular determinants required for selective interactions between the thyroid hormone receptor homodimer and the nuclear receptor corepressor N-CoR. *J Mol Biol* 396: 747–760, 2010.
46. Kitatsuji C, Izumi K, Nambu S, Kurogochi M, Uchida T, Nishimura SI, Iwai K, O'Brian MR, Ikeda-Saito M, and Ishimori K. Protein oxidation mediated by heme-induced active site conversion specific for heme-regulated transcription factor, iron response regulator. *Sci Rep* 6: 18703, 2016.
47. Ko CH and Takahashi JS. Molecular components of the mammalian circadian clock. *Hum Mol Genet* 15: R271–R277, 2006.
48. Kubota Y, Nomura K, Katoh Y, Yamashita R, Kaneko K, and Furuyama K. Novel mechanisms for heme-dependent degradation of ALAS1 protein as a component of negative feedback regulation of heme biosynthesis. *J Biol Chem* 291: 20516–20529, 2016.
49. Kühl T, Sahoo N, Nikolajski M, Schlott B, Heinemann SH, and Imhof D. Determination of heme-binding characteristics of proteins by a combinatorial peptide library approach. *Chembiochem* 12: 2846–2855, 2011.
50. Kühl T, Wißbrock A, Goradia N, Sahoo N, Galler K, Neugebauer U, Popp J, Heinemann SH, Ohlenschläger O, and Imhof D. Analysis of Fe(III) heme binding to cysteine-containing heme-regulatory motifs in proteins. *ACS Chem Biol* 8: 1785–1793, 2013.
51. Kumar N, Solt LA, Wang Y, Rogers PM, Bhattacharyya G, Kamenecka TM, Staybrook KR, Crumbley C, Floyd ZE, Gimble JM, Griffin PR, and Burris TP. Regulation of adipogenesis by natural and synthetic REV-ERB ligands. *Endocrinology* 151: 3015–3025, 2010.
52. Lathrop JT and Timko MP. Regulation by heme of mitochondrial protein-transport through a conserved amino-acid motif. *Science* 259: 522–525, 1993.
53. Leichert LI, Gehrke F, Gudiseva HV, Blackwell T, Ilbert M, Walker AK, Strahler JR, Andrews PC, and Jakob U. Quantifying changes in the thiol redox proteome upon oxidative stress *in vivo*. *Proc Natl Acad Sci U S A* 105: 8197–8202, 2008.
54. Liu M, Tanaka WN, Zhu H, Xie G, Dooley DM, and Lei B. Direct heme transfer from IsdA to IsdC in the iron-regulated surface determinant (Isd) heme acquisition system of *Staphylococcus aureus*. *J Biol Chem* 283: 6668–6676, 2008.
55. Maines MD. The heme oxygenase system: a regulator of second messenger gases. *Annu Rev Pharmacol Toxicol* 37: 517–554, 1997.
56. Maines MD, Trakshel GM, and Kutty RK. Characterization of two constitutive forms of rat-liver microsomal heme oxygenase: only one molecular-species of the enzyme is inducible. *J Biol Chem* 261: 411–419, 1986.
57. Mansuy D, Duppe W, Ruf HH, and Ullrich V. Phosphines as ligand to microsomal cytochrome-P450. *Hoppe Seyler's Z Physiol Chem* 355: 1341–1349, 1974.
58. Marvin KA, Reinking JL, Lee AJ, Pardee K, Krause HM, and Burstyn JN. Nuclear receptors *Homo sapiens* Rev-erb β and *Drosophila melanogaster* E75 are thiolate-ligated heme proteins which undergo redox-mediated ligand switching and bind CO and NO. *Biochemistry* 48: 7056–7071, 2009.
59. Matta-Camacho E, Banerjee S, Hughes TS, Solt LA, Wang Y, Burris TP, and Kojetin DJ. Structure of REV-ERB β ligand-binding domain bound to a porphyrin antagonist. *J Biol Chem* 289: 20054–20066, 2014.
60. McCoubrey WK, Huang TJ, and Maines MD. Heme oxygenase-2 is a hemoprotein and binds heme through heme regulatory motifs that are not involved in heme catalysis. *J Biol Chem* 272: 12568–12574, 1997.
61. Miki T, Matsumoto T, Zhao Z, and Lee CC. p53 regulates Period2 expression and the circadian clock. *Nat Commun* 4: 2444, 2013.
62. Mikanova M, Igarashi J, Minami M, Sagami I, Yamauchi S, Kurokawa H, and Shimizu T. Characterization of heme-regulated eIF2 α kinase: roles of the N-terminal domain in the oligomeric state, heme binding, catalysis, and inhibition. *Biochemistry* 45: 9894–9905, 2006.
63. Munakata H, Sun JY, Yoshida K, Nakatani T, Honda E, Hayakawa S, Furuyama K, and Hayashi N. Role of the heme regulatory motif in the heme-mediated inhibition of mitochondrial import of 5-aminolevulinic synthase. *J Biochem* 136: 233–238, 2004.
64. Nygaard TK, Blouin GC, Liu M, Fukumura M, Olson JS, Fabian M, Dooley DM, and Lei B. The mechanism of direct heme transfer from the streptococcal cell surface protein Shp to HtsA of the HtsABC transporter. *J Biol Chem* 281: 20761–20771, 2006.
65. Ogawa K, Sun J, Taketani S, Nakajima O, Nishitani C, Sassa S, Hayashi N, Yamamoto M, Shibahara S, Fujita H, and Igarashi K. Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. *EMBO J* 20: 2835–2843, 2001.

66. Pardee KI, Xu X, Reinking J, Schuetz A, Dong A, Liu S, Zhang R, Tiefenbach J, Lajoie G, Plotnikov AN, Botchkarev A, Krause HM, and Edwards A. The structural basis of gas-responsive transcription by the human nuclear hormone receptor REV-ERB β . *PLoS Biol* 7: e1000043, 2009.
67. Pfeifer K, Kim K-S, Kogan S, and Guarente L. Functional dissection and sequence of yeast HAP1 activator. *Cell* 56: 291–301, 1989.
68. Phelan CA, Gampe RT, Lambert MH, Parks DJ, Montana V, Bynum J, Broderick TM, Hu X, Williams SP, Nolte RT, and Lazar MA. Structure of Rev-erb α bound to N-CoR reveals a unique mechanism of nuclear receptor-corepressor interaction. *Nat Struct Mol Biol* 17: 808–814, 2010.
69. Qi Z, Hamza I and O'Brian MR. Heme is an effector molecule for iron-dependent degradation of the bacterial iron response regulator (Irr) protein. *Proc Natl Acad Sci U S A* 96: 13056–13061, 1999.
70. Raghuram S, Stayrook KR, Huang P, Rogers PM, Nosie AK, McClure DB, Burris LL, Khorasanizadeh S, Burris TP, and Rastinejad F. Identification of heme as the ligand for the orphan nuclear receptors REV-ERB α and REV-ERB β . *Nat Struct Mol Biol* 14: 1207–1213, 2007.
71. Ragsdale SW and Yi L. Thiol/disulfide redox switches in the regulation of heme binding to proteins. *Antioxid Redox Signal* 14: 1039–1047, 2011.
72. Raspé E, Duez H, Mansén A, Fontaine C, Fiévet C, Fruchart J-C, Vennström B, and Staels B. Identification of Rev-erb α as a physiological repressor of apoC-III gene transcription. *J Lipid Res* 43: 2172–2179, 2002.
73. Reppert SM and Weaver DR. Coordination of circadian timing in mammals. *Nature* 418: 935–941, 2002.
74. Robbins AH and Stout CD. Structure of activated aconitase: formation of the [4Fe-4S] cluster in the crystal. *Proc Natl Acad Sci U S A* 86: 3639–3643, 1989.
75. Ruf HH and Wende P. Hyperporphyrin spectra of ferric dimercaptide heme complexes: models for ferric cytochrome P450-thiol complexes. *J Am Chem Soc* 99: 5499–5500, 1977.
76. Sancar A. Regulation of the mammalian circadian clock by cryptochrome. *J Biol Chem* 279: 34079–34082, 2004.
77. Schubert E, Florin N, Duthie F, Brewitz HH, Kühl T, Imhof D, Hagelueken G, and Schiemann O. Spectroscopic studies on peptides and proteins with cysteine-containing heme regulatory motifs (HRM). *J Inorg Biochem* 148: 49–56, 2015.
78. Schuller DJ, Wilks A, de Montellano PRO, and Poulos TL. Crystal structure of human heme oxygenase-1. *Nat Struct Biol* 6: 860–867, 1999.
79. Shen J, Sheng X, Chang Z, Wu Q, Wang S, Xuan Z, Li D, Wu Y, Shang Y, Kong X, Yu L, Li L, Ruan K, Hu H, Huang Y, Hui L, Xie D, Wang F, and Hu R. Iron metabolism regulates p53 signaling through direct heme-p53 interaction and modulation of p53 localization, stability, and function. *Cell Rep* 7: 180–193, 2014.
80. Spencer ALM, Bagai I, Becker DF, Zuiderweg ERP, and Ragsdale SW. Protein/protein interactions in the mammalian heme degradation pathway: heme oxygenase-2, cytochrome P450 reductase, and biliverdin reductase. *J Biol Chem* 289: 29836–29858, 2014.
81. Strickland S, Palmer G, and Massey V. Determination of dissociation constants and specific rate constants of enzyme-substrate (or protein-ligand) interactions from rapid reaction kinetic data. *J Biol Chem* 250: 4048–4052, 1975.
82. Sun JY, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, Tashiro S, Takahashi S, Shibahara S, Alam J, Taketo MM, Yamamoto M, and Igarashi K. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. *EMBO J* 21: 5216–5224, 2002.
83. Sun SF, Sono M, and Dawson JH. Mono- and bisphosphine-ligated H93G myoglobin: spectral models for ferrous-phosphine and ferrous-CO cytochrome P450. *J Inorg Biochem* 127: 238–245, 2013.
84. Sundaramoorthy M, Terner J, and Poulos TL. The crystal structure of chloroperoxidase: a heme peroxidase-cytochrome P450 functional hybrid. *Structure* 3: 1367–1377, 1995.
85. Suzuki H, Tashiro S, Hira S, Sun JY, Yamazaki C, Zenke Y, Ikeda-Saito M, Yoshida M, and Igarashi K. Heme regulates gene expression by triggering Crl1-dependent nuclear export of Bach1. *EMBO J* 23: 2544–2553, 2004.
86. Varfaj F, Lampe JN, and de Montellano PRO. Role of cysteine residues in heme binding to human heme oxygenase-2 elucidated by two-dimensional NMR spectroscopy. *J Biol Chem* 287: 35181–35191, 2012.
87. Vukomanovic D, Rahman MN, Maines MD, Ozolins TRS, Szarek WA, Jia ZJ, and Nakatsu K. Cysteine-independent activation/inhibition of heme oxygenase-2. *Med Gas Res* 6: 10–13, 2016.
88. Wang J and Lazar MA. Bifunctional role of Rev-erb α in adipocyte differentiation. *Mol Cell Biol* 28: 2213–2220, 2008.
89. Wang J, Li Y, Zhang M, Liu Z, Wu C, Yuan H, Li Y-Y, Zhao X, and Lu H. A zinc finger HIT domain-containing protein, ZNHIT-1, interacts with orphan nuclear hormone receptor Rev-erb β and removes Rev-erb β -induced inhibition of apoCIII transcription. *FEBS J* 274: 5370–5381, 2007.
90. Wang J, Liu N, Liu Z, Li Y, Song C, Yuan H, Li Y-y, Zhao X, and Lu H. The orphan nuclear receptor Rev-erb β recruits Tip60 and HDAC1 to regulate *apolipoprotein CIII* promoter. *Biochim Biophys Acta* 1783: 224–236, 2008.
91. Wang J, Yin L, and Lazar MA. The orphan nuclear receptor Rev-erb α regulates circadian expression of plasminogen activator inhibitor type 1. *J Biol Chem* 281: 33842–33848, 2006.
92. Wang TA, Yu YV, Govindaiah G, Ye X, Artinian L, Coleman TP, Sweedler JV, Cox CL, and Gillette MU. Circadian rhythm of redox state regulates excitability in suprachiasmatic nucleus neurons. *Science* 337: 839–842, 2012.
93. Woo E-J, Jeong DG, Lim M-Y, Kim SJ, Kim K-J, Yoon S-M, Park B-C, and Ryu SE. Structural insight into the constitutive repression function of the nuclear receptor Rev-erb β . *J Mol Biol* 373: 735–744, 2007.
94. Yang J, Kim KD, Lucas A, Drahos KE, Santos CS, Mury SP, Capelluto DGS, and Finkielstein CV. A novel heme-regulatory motif mediates heme-dependent degradation of the circadian factor Period 2. *Mol Cell Biol* 28: 4697–4711, 2008.
95. Yang J, Panek HR, and O'Brian MR. Oxidative stress promotes degradation of the Irr protein to regulate haem biosynthesis in *Bradyrhizobium japonicum*. *Mol Microbiol* 60: 209–218, 2006.
96. Yang JH, Ishimori K, and O'Brian MR. Two heme binding sites are involved in the regulated degradation of the bacterial iron response regulator (Irr) protein. *J Biol Chem* 280: 7671–7676, 2005.

97. Yang JH, Sangwan I, Lindemann A, Hauser F, Hennecke H, Fischer HM, and O'Brian MR. *Bradyrhizobium japonicum* senses iron through the status of haem to regulate iron homeostasis and metabolism. *Mol Microbiol* 60: 427–437, 2006.
98. Yi L, Jenkins PM, Leichert LI, Jakob U, Martens JR, and Ragsdale SW. Heme regulatory motifs in heme oxygenase-2 form a thiol/disulfide redox switch that responds to the cellular redox state. *J Biol Chem* 284: 20556–20561, 2009.
99. Yi L and Ragsdale SW. Evidence that the heme regulatory motifs in heme oxygenase-2 serve as a thiol/disulfide redox switch regulating heme binding. *J Biol Chem* 282: 21056–21067, 2007.
100. Yin L, Joshi S, Wu N, Tong X, and Lazar MA. E3 ligases Arf-bp1 and Pam mediate lithium-stimulated degradation of the circadian heme receptor Rev-erb α . *Proc Natl Acad Sci U S A* 107: 11614–11619, 2010.
101. Yin L, Wang J, Klein PS, and Lazar MA. Nuclear receptor Rev-erb α is a critical lithium-sensitive component of the circadian clock. *Science* 311: 1002–1005, 2006.
102. Yin L, Wu N, Curtin JC, Qatanani M, Szwergold NR, Reid RA, Waitt GM, Parks DJ, Pearce KH, Wisely GB, and Lazar MA. Rev-erb α , a heme sensor that coordinates metabolic and circadian pathways. *Science* 318: 1786–1789, 2007.
103. Zenke-Kawasaki Y, Dohi Y, Katoh Y, Ikura T, Ikura M, Asahara T, Tokunaga F, Iwai K, and Igarashi K. Heme induces ubiquitination and degradation of the transcription factor Bach1. *Mol Cell Biol* 27: 6962–6971, 2007.
104. Zhang H, Chen YQ, Keane FM, and Gorrell MD. Advances in understanding the expression and function of dipeptidyl peptidase 8 and 9. *Mol Cancer Res* 11: 1487–1496, 2013.
105. Zhang L and Guarente L. Heme binds to a short sequence that serves a regulatory function in diverse proteins. *EMBO J* 14: 313–320, 1995.
106. Zhang L and Hach A. Molecular mechanism of heme signalling in yeast: the transcriptional activator Hap1 serves as the key mediator. *Cell Mol Life Sci* 56: 415–426, 1999.

Address correspondence to:
 Dr. Stephen W. Ragsdale
 Department of Biological Chemistry
 University of Michigan
 1150 W. Medical Center Dr, 5220D MSRBIII
 Ann Arbor, MI 48109

E-mail: sragdsal@umich.edu

Date of first submission to ARS Central, September 12, 2017;
 date of acceptance, October 5, 2017.

Abbreviations Used

ALAS1 and ALAS2 = aminolevulinic acid synthase-1 nonspecific, and erythroid-specific aminolevulinic acid synthase-2
 CO = carbon monoxide
 CPO = chloroperoxidase
 Cry = cryptochrome protein
 DGCR8 = DiGeorge critical region
 DP8 = dipeptidyl peptidase 8
 ENDOR = electron nuclear double resonance
 EPR = electron paramagnetic resonance
 EXAFS = extended X-ray absorption fine structure
 FLRev-erb β = full-length Rev-erb β
 Hap-1 = heme activator protein-1
 HDAC1 = histone deacetylase 1
 HO or HO1 or HO2 = heme oxygenase and heme oxygenase isoform 1 or 2
 HO2_{core} = HO2 spanning residues 1–248
 HO2^R = HO2 in the disulfide bond-reduced form
 HO2_{sol} = HO2 spanning residues 1–288
 HO2_{tail} = HO2 spanning residues 213–288
 HRI = heme-regulated inhibitor, or heme-regulated eIF2 α kinase
 HRM = heme regulatory motif
 ID = interaction domain
 IL-36 α = interleukin-36 α
 IRP2 = iron regulatory protein 2
 Irr = bacterial iron response regulator
 ITC = isothermal titration calorimetry
 LBD = ligand-binding domain
 MCD = magnetic circular dichroism
 NCoR1 = nuclear receptor corepressor 1
 NMR = nuclear magnetic resonance
 NO = nitric oxide
 NR = nuclear receptor
 Per = period protein
 PPIX = protoporphyrin IX
 RH = regulatory heme
 ROR α = RAR-related orphan receptor α
 SCN = suprachiasmatic nucleus
 XAS = X-ray absorption